2024
Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRisk AssessmentRisk FactorsSecondary PreventionStrokeUnited KingdomUnited StatesConceptsMyocardial infarctionPrevention scoreSecondary preventionImplementation of preventive therapyNational cohortUK BiobankAntiplatelet therapy useGuideline-directed therapyPrevention profilesBlood pressure controlAdherence to guideline-directed therapyLow-density lipoprotein controlNeighborhood deprivation levelHistory of strokeVascular risk profileStatin useAntiplatelet useTherapy usePreventive therapyComparison to participantsPrevention criteriaCross-sectional analysisBlood pressurePatientsPressure control
2018
Accounting for Nonadherence
Spatz ES, Curtis JP. Accounting for Nonadherence. Circulation 2018, 137: 2139-2141. PMID: 29760226, DOI: 10.1161/circulationaha.118.033532.Commentaries, Editorials and LettersNational Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
Salami JA, Warraich HJ, Valero‐Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Katzen BT, Lloyd‐Jones D, Krumholz HM, Nasir K. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Journal Of The American Heart Association 2018, 7: e007132. PMID: 29358195, PMCID: PMC5850149, DOI: 10.1161/jaha.117.007132.Peer-Reviewed Original ResearchAdultAgedAtherosclerosisDatabases, FactualDrug CostsDrug PrescriptionsDyslipidemiasFemaleHealth Care SurveysHealth ExpendituresHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLongitudinal StudiesMaleMedically UninsuredMiddle AgedPractice Patterns, Physicians'Racial GroupsRetrospective StudiesRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeUnited States
2017
Patient–Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States
Okunrintemi V, Spatz ES, Di Capua P, Salami JA, Valero-Elizondo J, Warraich H, Virani SS, Blaha MJ, Blankstein R, Butt AA, Borden WB, Dharmarajan K, Ting H, Krumholz HM, Nasir K. Patient–Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States. Circulation Cardiovascular Quality And Outcomes 2017, 10: e003635. PMID: 28373270, DOI: 10.1161/circoutcomes.117.003635.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAspirinAtherosclerosisCommunicationEmergency Service, HospitalFemaleHealth Care CostsHealth Care SurveysHealth ExpendituresHealth StatusHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLength of StayMaleMental HealthMiddle AgedOdds RatioPatient Reported Outcome MeasuresPatient-Centered CarePhysician-Patient RelationsPlatelet Aggregation InhibitorsQuality Indicators, Health CareRisk FactorsUnited StatesYoung AdultConceptsAtherosclerotic cardiovascular diseasePatient-provider communicationHealthcare resource utilizationPatient-reported outcomesCardiovascular diseaseHealth Plans SurveyMedical Expenditure Panel Survey cohortHigher annual healthcare expendituresRepresentative US adult populationHealthcare expendituresAtherosclerotic cardiovascular disease (ASCVD) patientsConsumer AssessmentEmergency room visitsEvidence-based therapiesAnnual healthcare expendituresCardiovascular disease patientsUS adult populationPlans SurveyMental health statusPatient-centered careOutcomes of interestASA useHospital stayRoom visitsPoor outcomeNational Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey
Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Lloyd-Jones D, Nasir K. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiology 2017, 2: 56-65. PMID: 27842171, DOI: 10.1001/jamacardio.2016.4700.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAtherosclerosisCardiovascular DiseasesDrug PrescriptionsDrugs, GenericFemaleHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLongitudinal StudiesMaleMiddle AgedRetrospective StudiesConceptsAtherosclerotic cardiovascular diseaseStatin useAdults 40 yearsUS adult populationAdult populationMedical Expenditure Panel Survey databaseRepresentative US adult populationUS adults 40 yearsRetrospective longitudinal cohort studyHigh-intensity doseHigh-risk groupLongitudinal cohort studyMedical Expenditure Panel SurveyGeneral adult populationBrand-name statinsCohort studyStatin usersCardiovascular diseaseMedical conditionsMAIN OUTCOMEUS adultsGeneral populationStatinsOOP costsGeneric statins
2016
Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study
Lu Y, Zhou S, Dreyer RP, Caulfield M, Spatz ES, Geda M, Lorenze NP, Herbert P, D'Onofrio G, Jackson EA, Lichtman JH, Bueno H, Spertus JA, Krumholz HM. Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study. American Heart Journal 2016, 183: 74-84. PMID: 27979045, PMCID: PMC5459396, DOI: 10.1016/j.ahj.2016.09.012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnticholesteremic AgentsCholesterol, HDLCholesterol, LDLFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLinear ModelsLipidsMaleMiddle AgedMyocardial InfarctionSex FactorsYoung AdultConceptsAcute myocardial infarctionLipid profileYoung womenLipoprotein cholesterolLipoprotein profileMyocardial infarctionTreatment utilizationLow-density lipoprotein cholesterolHigh-density lipoprotein cholesterolLow HDL cholesterol levelsYoung adultsHigh-intensity doseMajor lipid abnormalitiesSex differencesAdverse lipid profileFavorable lipoprotein profileHDL cholesterol ratioLower total cholesterolHDL cholesterol levelsHigher HDL cholesterolImportant risk factorHigher mortality riskMultivariate regression analysisVIRGO StudyCardiovascular outcomes
2014
Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China
Zheng X, Dreyer RP, Hu S, Spatz ES, Masoudi FA, Spertus JA, Nasir K, Li X, Li J, Wang S, Krumholz HM, Jiang L. Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China. Heart 2014, 101: 349. PMID: 25510395, PMCID: PMC4453015, DOI: 10.1136/heartjnl-2014-306456.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overChinaDrug UtilizationFemaleHospital MortalityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRetrospective StudiesRural PopulationSex FactorsUrban PopulationConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionGender-age interactionHospital mortalityEarly mortalityMyocardial infarctionChina PEACE-Retrospective AMI StudyHospital mortality rateYears of ageAge-specific gender differencesPatient characteristicsHospital characteristicsMultivariable modelMortality rateGender differencesChinese populationMortalityYounger groupChinese hospitalsWomenAMI studyMenInfarctionAgeRepresentative sample
2011
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez G, Spatz E, Jablecki C, Phillips P. Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clinic Journal Of Medicine 2011, 78: 393-403. PMID: 21632911, DOI: 10.3949/ccjm.78a.10073.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicDiagnosis, DifferentialHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMuscle WeaknessMuscular DiseasesMyositisRhabdomyolysisRisk Factors
2009
From Here to JUPITER
Spatz ES, Canavan ME, Desai MM. From Here to JUPITER. Circulation Cardiovascular Quality And Outcomes 2009, 2: 41-48. PMID: 20031811, DOI: 10.1161/circoutcomes.108.832592.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCardiovascular DiseasesC-Reactive ProteinEvidence-Based MedicineFemaleHealth SurveysHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsLipoproteins, LDLMaleMiddle AgedNutrition SurveysPatient SelectionPractice Guidelines as TopicRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTime FactorsConceptsHigh-sensitivity C-reactive proteinLow-density lipoproteinStatin therapyC-reactive proteinElevated high-sensitivity C-reactive protein levelsHigh-sensitivity C-reactive protein levelsElevated low-density lipoprotein levelsGoal low-density lipoproteinIntervention Trial Evaluating RosuvastatinC-reactive protein levelsOlder personsLow-density lipoprotein levelsUse of statinsNutrition Examination SurveyCardiovascular riskMetabolic syndromeLipoprotein levelsPrimary preventionExamination SurveyTreatment recommendationsNational HealthElderly adultsTherapyStatinsOlder adults